Patents by Inventor Craig Robert STEWART

Craig Robert STEWART has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis of Mcl-1 inhibitor
    Patent number: 11149024
    Abstract: Disclosed are intermediates and methods of synthesizing Compound 1.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 19, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Craig Robert Stewart, Simon Hardy, Andrew Stark, Alexander Hird, Qing Ye, Xiaolan Zheng, Cati Ferrar, Jan Koek, Debasis Hazra
  • SYNTHESIS OF MCL-1 INHIBITOR
    Publication number: 20210122735
    Abstract: Disclosed are intermediates and methods of synthesizing Compound 1.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 29, 2021
    Applicant: ASTRAZENECA AB
    Inventors: Craig Robert STEWART, Simon HARDY, Andrew STARK, Alexander HIRD, Qing YE, Xiaolan ZHENG, Cati FERRAR, Jan KOEK, Debasis HAZRA
  • Camsylate salt
    Patent number: 10548882
    Abstract: A camsylate salt of (1r,1?R,4R)-4-methoxy-5?-methyl-6?-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3?H-dispiro[cyclohexane-1,2?-inden-1?2?-imidazole]-4?-amine, pharmaceutical compositions containing the salt and therapeutic uses of the salt for treating A?-related pathologies such as Alzheimer's Disease, Down's syndrome, ?-amyloid angiopathy and conditions such as dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: February 4, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Martin Hans Bohlin, Craig Robert Stewart
  • Compound
    Patent number: 9975881
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 22, 2018
    Assignee: ASTRAZENECA AB
    Inventors: Stephen Connolly, Mark Richard Ebden, Iain Alastair Stewart Walters, Thomas Langer, Alan Robert Steven, Craig Robert Stewart, Paula Margaret Tomlin, Andrew John Williams
  • Novel Compound
    Publication number: 20160108023
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Inventors: Stephen Connolly, Mark Richard Ebden, Iain Alastair Stewart Walters, Thomas Langer, Alan Robert Steven, Craig Robert Stewart, Paula Margaret Tomlin, Andrew John Williams
  • Compound
    Patent number: 9221782
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: December 29, 2015
    Assignee: AstraZeneca AB
    Inventors: Stephen Connolly, Mark Richard Ebden, Iain Alastair Stewart Walters, Thomas Langer, Alan Robert Steven, Craig Robert Stewart, Paula Margaret Tomlin, Andrew John Williams
  • Novel Compound
    Publication number: 20140228339
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Application
    Filed: April 15, 2014
    Publication date: August 14, 2014
    Applicant: AstraZeneca AB
    Inventors: Stephen Connolly, Mark Richard Ebden, Iain Alastair Stewart Walters, Thomas Langer, Alan Robert Steven, Craig Robert Stewart, Paula Margaret Tomlin, Andrew John Williams
  • Compound
    Patent number: 8735413
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: May 27, 2014
    Assignee: AstraZeneca AB
    Inventors: Stephen Connolly, Mark Richard Ebden, Iain Alastair Stewart Walters, Thomas Langer, Alan Robert Steven, Craig Robert Stewart, Paula Margaret Tomlin, Andrew John Williams
  • Camsylate Salt
    Publication number: 20140031379
    Abstract: A camsylate salt of (1r,1?R,4R)-4-methoxy-5?-methyl-6?-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3?H-dispiro[cyclohexane-1,2?-inden-1?2?-imidazole]-4?-amine, pharmaceutical compositions containing the salt and therapeutic uses of the salt for treating A?-related pathologies such as Alzheimer's Disease, Down's syndrome, ?-amyloid angiopathy and conditions such as dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: June 13, 2013
    Publication date: January 30, 2014
    Applicant: ASTRAZENECA AB
    Inventors: Martin Hans Bohlin, Craig Robert Stewart
  • NOVEL COMPOUND
    Publication number: 20130040926
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Application
    Filed: July 11, 2012
    Publication date: February 14, 2013
    Inventors: Stephen CONNOLLY, Mark Richard EBDEN, Iain Alastair Stewart WALTERS, Thomas LANGER, Alan Robert STEVEN, Craig Robert STEWART, Paula Margaret TOMLIN, Andrew John WILLIAMS